|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-4
|
|
pubmed:abstractText |
To determine the safety, tolerability, and bioactivity of KH902, a fully human fusion protein containing key domains from vascular endothelial growth factor receptors 1 and 2 with human immunoglobulin Fc.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1549-4713
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
118
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
672-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21146224-Aged,
pubmed-meshheading:21146224-Angiogenesis Inhibitors,
pubmed-meshheading:21146224-Choroidal Neovascularization,
pubmed-meshheading:21146224-Dose-Response Relationship, Drug,
pubmed-meshheading:21146224-Female,
pubmed-meshheading:21146224-Fluorescein Angiography,
pubmed-meshheading:21146224-Follow-Up Studies,
pubmed-meshheading:21146224-Humans,
pubmed-meshheading:21146224-Intraocular Pressure,
pubmed-meshheading:21146224-Intravitreal Injections,
pubmed-meshheading:21146224-Macular Degeneration,
pubmed-meshheading:21146224-Male,
pubmed-meshheading:21146224-Maximum Tolerated Dose,
pubmed-meshheading:21146224-Prognosis,
pubmed-meshheading:21146224-Prospective Studies,
pubmed-meshheading:21146224-Recombinant Fusion Proteins,
pubmed-meshheading:21146224-Tomography, Optical Coherence,
pubmed-meshheading:21146224-Visual Acuity
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.
|
|
pubmed:affiliation |
Department of Ophthalmology, West China Hospital, Chengdu, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
